Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
Innovent Biologics (HKEX: 01801), a global biopharmaceutical company, announces its participation in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco. Dr. De-Chao Michael Yu, the company's Founder, Chairman and CEO, will deliver a presentation on January 16 at 8:30 a.m. PST, covering business updates, strategic priorities, and future outlook.
The conference, recognized as the industry's largest healthcare investment symposium, will host over 8,000 investors and representatives from 550 global healthcare companies. Dr. Yu will also participate in a panel discussion on 'China Biopharma Industry Global Expansion Strategy' on January 15 at 2:15 p.m. PST.
Innovent, which develops and commercializes medicines for oncology, cardiovascular, metabolic, autoimmune, ophthalmology, and other major diseases, will provide live audio webcasts and presentation slides through their website.
Innovent Biologics (HKEX: 01801), un'azienda biopharma globale, annuncia la sua partecipazione al 43° Annual J.P. Morgan Healthcare Conference che si terrà dal 13 al 16 gennaio 2025 a San Francisco. Il Dr. De-Chao Michael Yu, fondatore, presidente e CEO dell'azienda, presenterà il 16 gennaio alle 8:30 ora PST, trattando aggiornamenti aziendali, priorità strategiche e prospettive future.
La conferenza, riconosciuta come il più grande simposio di investimento in sanità del settore, ospiterà oltre 8.000 investitori e rappresentanti di 550 aziende sanitarie globali. Il Dr. Yu parteciperà anche a una discussione di panel sulla 'Strategia di Espansione Globale dell'Industria Biopharma Cinese' il 15 gennaio alle 14:15 ora PST.
Innovent, che sviluppa e commercializza farmaci per oncologia, cardiovascolare, metabolica, autoimmune, oftalmologia e altre malattie principali, fornirà webcast audio dal vivo e diapositive delle presentazioni attraverso il loro sito web.
Innovent Biologics (HKEX: 01801), una compañía biofarmacéutica global, anuncia su participación en la 43ª Conferencia Anual de Salud J.P. Morgan del 13 al 16 de enero de 2025 en San Francisco. El Dr. De-Chao Michael Yu, fundador, presidente y CEO de la compañía, realizará una presentación el 16 de enero a las 8:30 a.m. PST, abarcando actualizaciones comerciales, prioridades estratégicas y perspectivas futuras.
La conferencia, reconocida como el simposio de inversión en salud más grande de la industria, albergará a más de 8,000 inversores y representantes de 550 empresas globales de salud. El Dr. Yu también participará en una discusión de panel sobre la 'Estrategia de Expansión Global de la Industria Biopharma de China' el 15 de enero a las 2:15 p.m. PST.
Innovent, que desarrolla y comercializa medicamentos para oncología, cardiovascular, metabólica, autoinmunitaria, oftalmología y otras enfermedades importantes, proporcionará transmisiones de audio en vivo y diapositivas de las presentaciones a través de su sitio web.
Innovent Biologics (HKEX: 01801), 글로벌 생물의약품 회사,는 2025년 1월 13일부터 16일까지 샌프란시스코에서 열리는 제43회 JP모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 창립자이자 회장, CEO인 Dr. De-Chao Michael Yu는 1월 16일 오전 8시 30분 PST에 비즈니스 업데이트, 전략적 우선사항 및 미래 전망을 다룬 발표를 진행할 예정입니다.
이 컨퍼런스는 업계에서 가장 큰 헬스케어 투자 심포지엄으로, 8,000명 이상의 투자자와 550개의 전 세계 헬스케어 기업의 대표들이 참석할 예정입니다. Dr. Yu는 또한 1월 15일 오후 2시 15분 PST에 '중국 바이오제약 산업의 글로벌 확장 전략'에 대한 패널 토론에 참여할 것입니다.
Innovent는 종양학, 심혈관, 대사, 자가 면역, 안과 및 기타 주요 질병을 위한 의약품 개발 및 상업화를 진행하며, 웹사이트를 통해 라이브 오디오 웹캐스트 및 프레젠테이션 슬라이드를 제공할 것입니다.
Innovent Biologics (HKEX: 01801), une entreprise biopharmaceutique mondiale, annonce sa participation à la 43e Conférence Annuelle du J.P. Morgan Healthcare du 13 au 16 janvier 2025 à San Francisco. Le Dr. De-Chao Michael Yu, fondateur, président et PDG de la société, fera une présentation le 16 janvier à 8h30 PST, abordant les mises à jour commerciales, les priorités stratégiques et les perspectives d'avenir.
La conférence, reconnue comme le plus grand symposium d'investissement dans le secteur de la santé, rassemblera plus de 8 000 investisseurs et représentants de 550 entreprises de santé à l'échelle mondiale. Le Dr. Yu participera également à une discussion en panel sur 'La Stratégie d'Expansion Globale de l'Industrie Biopharma Chinoise' le 15 janvier à 14h15 PST.
Innovent, qui développe et commercialise des médicaments pour l'oncologie, les maladies cardiovasculaires, métaboliques, auto-immunes, ophtalmologiques et d'autres maladies majeures, fournira des webdiffusions audio en direct et des diapositives de présentation sur leur site web.
Innovent Biologics (HKEX: 01801), ein globales biopharmazeutisches Unternehmen, kündigt seine Teilnahme an der 43. J.P. Morgan Healthcare-Konferenz vom 13. bis 16. Januar 2025 in San Francisco an. Dr. De-Chao Michael Yu, der Gründer, Vorsitzende und CEO des Unternehmens, wird am 16. Januar um 8:30 Uhr PST eine Präsentation halten, die sich mit Unternehmensupdates, strategischen Prioritäten und zukünftigen Aussichten befasst.
Die Konferenz, die als das größte Investitionssymposium im Gesundheitswesen der Branche anerkannt ist, wird über 8.000 Investoren und Vertreter von 550 globalen Gesundheitsunternehmen versammeln. Dr. Yu wird außerdem am 15. Januar um 14:15 Uhr PST an einer Podiumsdiskussion über die 'Globale Expansionsstrategie der chinesischen Biopharma-Industrie' teilnehmen.
Innovent, das Arzneimittel für Onkologie, Herz-Kreislauf-Erkrankungen, Stoffwechsel, Autoimmunerkrankungen, Augenheilkunde und andere schwerwiegende Erkrankungen entwickelt und kommerzialisiert, wird Live-Audio-Webcasts und Präsentationsfolien über ihre Webseite bereitstellen.
- None.
- None.
SAN FRANCISCO and
The 43rd J.P. Morgan Annual Healthcare Conference will be held from January 13 to 16, 2025 in
Company Presentation
Time: Thursday, January 16, at 08:30 a.m. PST
Speaker: Dr. De-Chao Michael Yu, the Founder, Chairman and CEO of Innovent
Live audio webcast:
Presentation slides：
https://www.innoventbio.com/InvestorsAndMedia/WebcastsAndPresentations
* will be available on the Innovent website - Investors & Media section after the live presentation
Panel Discussion
Time: Wednesday, January 15, at 2:15 p.m. PST
Theme: China Biopharma Industry Global Expansion Strategy
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 13 products in the market. It has 4 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.
Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
View original content:https://www.prnewswire.com/news-releases/innovent-to-participate-and-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302342374.html
SOURCE Innovent Biologics
FAQ
When and where will Innovent present at the 2025 J.P. Morgan Healthcare Conference?
What topics will be covered in Innovent's presentation at the 2025 JPM Healthcare Conference?
How can investors access Innovent's JPM Healthcare Conference presentation?
What panel discussion will Innovent participate in at the 2025 JPM Healthcare Conference?
What therapeutic areas does Innovent focus on?
